MeiraGTx Holdings (MGTX) on Tuesday reported positive preliminary data from a phase 1 trial of AAV-hAQP1 to treat grade 2/3 radiation-induced xerostomia, a...
MeiraGTx Holdings (MGTX), a clinical stage gene therapy company, reported Wednesday a Q3 diluted net loss of $0.59 per share, compared with a $0.17 loss a...
Richard Giroux, CFO & COO, on October 19, 2021, sold 22,000 shares in Meiragtx Holdings (MGTX) for $461,777. Following the Form 4 filing with the SEC,...
Alexandria Forbes, Director, President and CEO, on October 18, 2021, sold 30,000 shares in Meiragtx Holdings (MGTX) for $520,687. Following the Form 4...
| Address | 430 East 29th Street New York, New York 10016 |
| Phone | +1.646.860.7985 |
| Number of Employees | 68 |
| Recent SEC Filing | 01/11/2022 4 |
| President, Chief Executive Officer & Director | Alexandria Forbes |
| Chief Operating & Financial Officer | Richard Giroux |
| Chief Medical Officer | Robert K. Zeldin |
| Chief Development Officer | Stuart Naylor |
| Price Open | $18.68 |
| Previous Close | $18.91 |
| 52 Week Range | $11.60 - 24.89 |
| Market Capitalization | $821.8 M |
| Shares Outstanding | 44.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.83 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -391.81% |
| Return on Equity | -37.57% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
